TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Insulin Resistance Before and During Pregnancy in Women With Polycystic Ovary Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of PCOS prior to pregnancy~* 18-40 years of age~* Documented BMI 30-40 kg/m2 (within 3 months prior to pregnancy or within 8 weeks of gestation)~* Either of Caucasian or African-American decent by self report.~* Pregnant or attempting pregnancy~Exclusion Criteria:~* Preexisting Diabetes (impaired glucose tolerance will not be an exclusion criterion because of the high prevalence of impaired glucose tolerance in the PCOS population).~* Hemoglobin \< 8 or hemoglobin \<10 with symptoms of anemia.~* Use of tobacco, alcohol or illicit substances.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- African-American women (Type: None): Observational study--no intervention
- Caucasian women (Type: None): Observational study--no intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Asian Patients With Hypercholesterolaemia in the UK - Rosuvastatin 5mg Versus Atorvastatin 10mg

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Self described Asian, first or second generation~* Male or female \> or = 18 years with primary hypercholesterolaemia.~Exclusion Criteria:~* Use of cholesterol lowering drugs from visit 1~* Homozygous familial hypercholesterolaemia~* Active arterial disease within 3 months of study entry~* Poorly controlled diabetes~* Uncontrolled hypothyroidism~* Active liver disease~* History of alcoh/drug abuse.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rosuvastatin (Type: ACTIVE_COMPARATOR): rosuvastatin 5 mg
- atorvastatin (Type: ACTIVE_COMPARATOR): atorvastatin 10 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Phased Radio Frequency Ablation System

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* History of symptomatic persistent or long-standing persistent atrial fibrillation~* Failure of at least one anti-arrhythmic drug~Exclusion Criteria:~* Structural heart disease~* Prior ablation in left atrium for AF~* Known sensitivities (or allergy) to heparin, warfarin, contrast media~* Contraindicated for MRI~* Invasive cardiovascular procedure performed or planned within 3 month period of ablation procedure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Ablation (Type: EXPERIMENTAL): Phased RF ablation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pain Catastrophizing and Prescription Opioid Craving

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years~* Chronic pain ( \> 3months)~* Prescription opioid use (\>3 months)~Exclusion Criteria:~* Current diagnosis of cancer~* Concurrent psychological therapy~* Other severe psychiatric conditions (schizophrenia, delusional disorder, psychotic disorder, dissociative disorder, and active suicidality)~* Any skin conditions on the hand (pain testing site)~* Non-English speaker~* No access to email or smart phone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Coping statement (Type: EXPERIMENTAL): Daily practice of pain coping statements for 7 days
- Control (Type: NO_INTERVENTION): No instruction about pain coping statement.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Fluorescence Angiography: Planning and Monitoring of Perforator Flaps

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* perforator flap reconstruction whatever the indication (cancer, trauma, malformations). The main targets are the fibula flaps, anterolateral thigh flaps and inferior epigastric flaps~* consenting patient~Exclusion Criteria:~* known indocyanine green allergy~* pregnant woman, parturient woman or nursing woman

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- add-on fluorescence angiography (Type: EXPERIMENTAL): The surgeon will prescribe the usual morphological assessment of the proposed flap:~* CT angiography for an anterolateral thigh flap or an epigastric inferior flap~* A Doppler ultrasonography for a fibula flap.~In addition to the usual radiological technique used to locate the perforating arteries, the patient will have a fluorescence angiography prior to surgery, another just after the end of surgery and then one every six hours during the next 4 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Music Therapy is Associated With Decreased Pain and Agitation in Intubated ICU Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* between 18 and 70 years old, requiring intubation andmechanical ventilation, requiring sedation with propofol or benzodiazepines and/or analgesia with narcotics~Exclusion Criteria:~* hearing loss, psychiatric illness, hemodynamically unstable (requirement for vasopressor support)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- With Music (Type: EXPERIMENTAL): This randomized group will receive music
- Control Arm (Type: PLACEBO_COMPARATOR): Will not receive music but will receive audio loop of recorded ICU sounds

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Adaptive Auditive Cueing as a Therapy for Freezing of Gait in Parkinson Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* must have more than 1 FOG episode/day~* must be patient in Ziekenhuis Oost Limburg (ZOL)~Exclusion Criteria:~* not able to speak Dutch~* cannot give informed consent (mental health)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Single group (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Completion of the Planned Treatment Period in the AL002-2 study.~* The participant is willing and able to give informed consent.~* Study partner who consents to study participation and who cares for/visits the participant at least 10 hours a week~Exclusion Criteria:~* Participants deemed not able to provide consent or assent by the Investigator or by local regulations.~* Participants who were prematurely and permanently discontinued from treatment in the parent study for safety reasons.~* Participation deemed inappropriate per Investigator discretion.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- AL002 Dose 1 (Type: EXPERIMENTAL): AL002 every 4 weeks
- AL002 Dose 2 (Type: EXPERIMENTAL): AL002 every 4 weeks
- AL002 Dose 3 (Type: EXPERIMENTAL): AL002 every 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Whole Blood Biospecimen Collection for Subjects With Chronic Granulomatous Disease (CGD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The participant is willing and able to provide written informed consent~* The participant is willing and able to provide appropriate photo identification~* Participants aged 18 to 85~* Participants have been diagnosed with Chronic Granulomatous Disease (CGD)~* Subjects who have a confirmed p47phox CGD mutation or Subjects who have a confirmed X-linked CGD mutation~Exclusion Criteria:~* Participants who are pregnant or are nursing~* Participants with a known history of HIV, hepatitis, or other infectious diseases~* Participants who have taken an investigational product in the last 30 days~* Participants who have experienced excess blood loss, including blood donation, defined as 250 mL in the last month or 500 mL in the previous two months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- CGD with p47phox phenotype (Type: None): None
- X-Linked CGD (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Clinical Outcomes Between Ketamine-midazolam and Morphine-midazolam for Continous Sedation in ICU Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \>12years of age.~2. Anticipated need for sedation for \>24hours.~Exclusion Criteria:~1. Hypertensive crisis i.e. sustained SBP \>200mmHg/DBP\>110mmHg~2. Status epilepticus~3. Ischemic heart disease and severe LV dysfunction~4. Persistent tachyarrythmias~5. History of mental illness~6. Hypersensitivity to ketamine, morphine or midazolam.~7. Tetanus -due to the muscle rigidity that may be caused by ketamine. Reasons for exclusions 1 to 4; Ketamine stimulates the sympathetic nervous system causing transient increase in myocardial work and blood pressure and has psychoactive effects

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ketamine-midazolam (Type: EXPERIMENTAL): Continous intravenous sedation with a colorless drug mixture in 50ml syringe containing 900mg ketamine and 36mg midazolam.
- Morphine-Midazolam (Type: ACTIVE_COMPARATOR): Continous intravenous sedation with a colourless drug mixture in 50ml syringes containing 54mg morphine and 36mg midazolam.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Histologically confirmed stage IIIA or IIIB NSCLC~* Patients must have measurable disease~* No previous chemotherapy, radiation therapy or other systemic therapy for their NSCLC.~* Age\>18 years~* Life expectancy \>12 months~* ECOG performance status 0-1~* Normal organ and marrow function~* Medically fit for surgery at time of enrollment.~* Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of the study. Women must have a negative pregnancy test prior to enrollment.~* Ability to understand and willingness to sign the consent form.~Exclusion Criteria:~* Previous chemotherapy, radiation therapy or any other systemic treatment for their NSCLC.~* Patients receiving any other investigational agents.~* Known metastatic disease (brain or any other site)~* History of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80 or with allergic reactions to compounds of similar chemical composition to carboplatin or other agents used in the study.~* Peripheral neuropathy \>grade 1~* Uncontrolled concurrent illness~* Pregnant women~* Weight loss\>10% in the past 3 months before diagnosis.~* Hyperglycemia - exclusion from PET analysis~* HIV positive patients receiving combination anti-retroviral therapy because of possible pharmacokinetic interactions with docetaxel and carboplatin or other agents administered during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemotherapy+Radiation+Surgery (Type: EXPERIMENTAL): 1. Concurrent weekly docetaxel at 20 mg/m2 and weekly carboplatin at an AUC of 2 with thoracic radiotherapy of 180-200cGy/day for 5/7 days to 45 Gy.~2. Complete surgical excision 3-6 weeks after completion of chemoradiotherapy.~3. No Surgery if patient is deemed unable to tolerate surgery, with completion to 61 Gy radiation~4. Consolidation after surgery: Docetaxel given at 75 mg/m2 every 3 weeks with carboplatin at AUC 6 every 3 weeks with concomitant growth factor support.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: New Beginnings Following Trauma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of trauma meeting past-month diagnostic criteria for posttraumatic stress disorder (PTSD; meeting diagnostic status on the DIAMOND PTSD Module and score greater than or equal to 36 on the PCL-5) and current or past diagnostic criteria for opioid use disorder (OUD).~* Enrolled in a methadone or buprenorphine treatment program in the state of Kentucky.~* 18 years of age or older and fluent in English (including being able to read and write in English).~* Participants on psychotropic medications and medications for opioid use disorder (methadone or buprenorphine) will be included if they have been maintained on a stable dose for at least 4 weeks prior to beginning the study and are willing to maintain a stable dosage throughout the study period; this procedure allows for a broader range of participants and avoids having outcomes assessment confounded by the initiation of medication during treatment.~* Participants in this study will also be required to sign a release of medical information for their methadone or buprenorphine clinic so that study staff can coordinate care with their methadone or buprenorphine provider.~* Willing to refrain from additional trauma-focused psychological treatment for the duration of the study.~Exclusion Criteria:~* Individuals diagnosed with psychological conditions that may be better addressed by alternative treatments. These conditions may include any history of psychotic disorders or dissociative identity disorder, manic episodes endorsed in the past year, current anorexia nervosa, and high risk of suicide.~* Individuals who endorse factors for which the treatment being studied (WET-I) may be contraindicated. These factors may include having no or limited memory of the trauma that would prevent the individual from engaging in written exposures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- 3-Week Baseline (Type: EXPERIMENTAL): Participants in this arm are randomized to a 3-week baseline period with repeated weekly assessment after the initial intake. Following the 3-week baseline, participants receive 5 weekly sessions of Written Exposure Therapy - Integrated (WET-I) followed by a 4-week follow-up phase with repeated weekly assessments.
- 5-Week Baseline (Type: EXPERIMENTAL): Participants in this arm are randomized to a 5-week baseline period with repeated weekly assessment after the initial intake. Following the 5-week baseline, participants receive 5 weekly sessions of Written Exposure Therapy - Integrated (WET-I) followed by a 4-week follow-up phase with repeated weekly assessments.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Oral Olanzapine Versus Haloperidol or Diazepam

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Accident \& Emergency Department patients~* Requiring oral drug sedation (as determined by an emergency clinician) will be enrolled.~Exclusion Criteria:~* known hypersensitivity or contraindication to the study drugs~* reversible aetiology for agitation (e.g. hypotension, hypoxia, hypoglycaemia)~* known pregnancy~* acute alcohol withdrawal~* refusal to take oral medication~* patients from correctional facilities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Olanzapine (Type: EXPERIMENTAL): oro-dispersible tablet (wafer)(Zyprexa), 5 mg, single dose
- Haloperidol (Type: ACTIVE_COMPARATOR): Haloperidol encapsulated tablet, 2 mg tablet, single dose
- Diazepam (Type: ACTIVE_COMPARATOR): Diazepam encapsulated tablet, 2mg tablet, single dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: SeaCare's Care Coordination for Diabetes Management in a Primary Care Office

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diabetes type II~Exclusion Criteria:~* Non-English speaking

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Care Coordination (Type: EXPERIMENTAL): Patients receive care coordination to improve their diabetes.
- control (Type: NO_INTERVENTION): patients with type II diabetes receive usual health care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hypericum vs Fluoxetine for Mild to Moderate Adolescent Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Adolescents aged 12 to 18 years~* Patients meeting the criteria for mild to moderate depression according to the DSM-IV scale~* Physical and laboratory examination at baseline compatible with study criteria~* ECG at baseline compatible with study criteria~* Score of at least 40 on the Children's Depression Rating Scale - Revised (CDRS-R) at baseline~Exclusion Criteria:~* Patients with psychosis, bi-polar disease, schizophrenia or significant developmental disorder~* Patients with epilepsy~* Patients with a history of alcohol or substance abuse in the past year~* Initiation of psychotherapy or behavioral therapy in the 2 months prior to screening or during the study.~* Patients who have previously failed to respond to SSRI's or SRNI's~* Patients who have been treated with antidepressants within 2 weeks of screening (4 weeks if fluoxetine)~* Patients with a contraindication to taking either Remotiv or fluoxetine or taking medication contraindicated when taking Remotiv or fluoxetine

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): hypericum 250mg tablets twice daily for 8 weeks
- B (Type: ACTIVE_COMPARATOR): fluoxetine 20mg - 40mg daily for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues